Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of a randomised phase III intergroup study initiated by the AIO and AGMT (ML18147)

被引：0
|
作者：
Greil, R. [1 ]
Arnold, D. [2 ]
Hegewisch-Becker, S.
Freier, W.
Steffens, C. -C. [3 ]
Bertram, M.
Schlichting, C. [4 ]
Andel, J. [5 ]
Taylor, M. [6 ]
Makrutzki, M. [7 ]
Kubicka, S. [8 ]
机构：
[1] Paracelsus Med Univ, Salzburg, Austria
[2] UCCH, Hubertus Wald Tumor Ctr, Hamburg, Germany
[3] MVZ Haematol Onkol Klin Dr Hancken, Stade, Germany
[4] Diakoniekrankenhaus gGmbH, Rotenburg, Germany
[5] LKH Steyr, Steyr, Austria
[6] Genentech Inc, Epidemiol Patient Reported Outcomes & Healthcare, San Francisco, CA 94080 USA
[7] F Hoffmann La Roche & Cie AG, Basel, Switzerland
[8] Kleiskliniken Reutlingen GmbH, Med Klin 1, Reutlingen, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：254 / 254
页数：1
相关论文
共 50 条
  • [31] SINGLE INSTITUTION RESULTS OF FIRST-LINE TREATMENT WITH BEVACIZUMAB PLUS CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER (MCRC)
    Barkmanova, Jaroslava
    Petruzelka, Lubos
    Sedlackova, Eva
    Vocka, Michal
    Hejduk, Karel
    Bortlicek, Zbynek
    ANNALS OF ONCOLOGY, 2014, 25
  • [32] A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
    Kim, Youjin
    Kim, Tae Won
    Han, Sae Won
    Ahn, Joong Bae
    Kim, Seung Tae
    Lee, Jeeyun
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER RESEARCH AND TREATMENT, 2019, 51 (03): : 1128 - 1134
  • [33] First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
    Zhou, Yu-Wen
    Long, Yi-Xiu
    Chen, Ye
    Liu, Ji-Yan
    Pu, Dan
    Huang, Jia-Yan
    Bi, Feng
    Li, Qiu
    Gou, Hong-Feng
    Qiu, Meng
    CANCER MEDICINE, 2021, 10 (10): : 3388 - 3402
  • [34] Prognostic value of baseline tumour markers in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab and/or cetuximab
    Cierbinski, A.
    Ruessel, J.
    Schmoll, H-J
    ONKOLOGIE, 2013, 36 : 72 - 72
  • [35] Olaparib plus /- bevacizumab versus bevacizumab plus fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX plus bevacizumab: Phase III LYNK-003 study.
    Mayo, Carlos Alberto
    Gurary, Ellen B.
    Marinello, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [36] Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
    Astrid Lièvre
    Emmanuelle Samalin
    Emmanuel Mitry
    Eric Assenat
    Christine Boyer-Gestin
    Céline Lepère
    Jean-Baptiste Bachet
    Fabienne Portales
    Jean-Nicolas Vaillant
    Marc Ychou
    Philippe Rougier
    BMC Cancer, 9
  • [37] Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
    Lievre, Astrid
    Samalin, Emmanuelle
    Mitry, Emmanuel
    Assenat, Eric
    Boyer-Gestin, Christine
    Lepere, Celine
    Bachet, Jean-Baptiste
    Portales, Fabienne
    Vaillant, Jean-Nicolas
    Ychou, Marc
    Rougier, Philippe
    BMC CANCER, 2009, 9 : 347
  • [38] SAFETY AND EFFICACY OF BEVACIZUMAB PLUS STANDARD FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST BEAT
    Van Cutsem, E.
    Berry, S.
    Michael, M.
    Kretzschmar, A.
    Rivera, F.
    DiBartolomeo, M.
    Mazier, M.
    Andre, N.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 125 - 125
  • [39] Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
    Hans-Joachim Lück
    Kristina Lübbe
    Mattea Reinisch
    Nicolai Maass
    Gabriele Feisel-Schwickardi
    Oliver Tomé
    Wolfgang Janni
    Mustafa Aydogdu
    Tanja Neunhöffer
    Angelika Ober
    Bahriye Aktas
    Tjoung-Won Park-Simon
    Claudia Schumacher
    Heinz-Gert Höffkes
    Thomas Illmer
    Harald Wagner
    Keyur Mehta
    Gunter von Minckwitz
    Valentina Nekljudova
    Sibylle Loibl
    Breast Cancer Research and Treatment, 2015, 149 : 141 - 149
  • [40] Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
    Lueck, Hans-Joachim
    Luebbe, Kristina
    Reinisch, Mattea
    Maass, Nicolai
    Feisel-Schwickardi, Gabriele
    Tome, Oliver
    Janni, Wolfgang
    Aydogdu, Mustafa
    Neunhoeffer, Tanja
    Ober, Angelika
    Aktas, Bahriye
    Park-Simon, Tjoung-Won
    Schumacher, Claudia
    Hoeffkes, Heinz-Gert
    Illmer, Thomas
    Wagner, Harald
    Mehta, Keyur
    von Minckwitz, Gunter
    Nekljudova, Valentina
    Loibl, Sibylle
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) : 141 - 149
12345